AGC Biologics A/S: Financial statements 2025
CVR: 25950941
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. That is a decrease of 2.8% compared with the year before. The profit margin was -16.7%. Equity in the 2025 report amounted to DKK 312,021,000. The solvency ratio was 7.7%. The company had 1,138 employees in the financial year.
- Revenue
- DKK 1,959,639,000
- Gross Profit
- DKK -91,242,000
- Profit/Loss
- DKK -328,010,000
- Equity
- DKK 312,021,000
- Total Assets
- DKK 4,050,883,000
- Employees
- 1,138
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 2B | -91.2M | -328M | 312M | 1138 |
| 2024 | 2B | 160.2M | -115M | 640M | 1019 |
| 2023 | 2.1B | 501.3M | 243.9M | 307.4M | 956 |
| 2022 | 2.5B | 937M | 598.9M | 661.3M | 894 |
| 2021 | 2.2B | 831.9M | 571.7M | 633.6M | 730 |
Official annual report
How creditworthy is AGC Biologics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
AGC Biologics A/S has published its annual report for 2024. Revenue came to DKK 2,016,194,000, and the net result was DKK -115,005,000.
As of April 1, 2025, Kasper Møller is registered as adm. dir. of AGC Biologics A/S.
As of April 1, 2025, Andrea Celia Porchia has stepped down as adm. dir. of AGC Biologics A/S.
As of March 3, 2025, Alberto Santagostino has joined the board of directors of AGC Biologics A/S.
As of March 3, 2025, Mai Iwaya has joined the board of directors of AGC Biologics A/S.
As of March 3, 2025, Akira Nakamura has left the board of directors of AGC Biologics A/S.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
